Intercept Pharmaceuticals Inc (ICPT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012209
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc (ICPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intercept Pharma Raises US$30 Million In Series C Financing 10
Partnerships 12
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Enters Into Co-Development Agreement With Servier 14
Licensing Agreements 15
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For INT-747 15
Equity Offering 17
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 17
Intercept Pharma Raises USD202 Million in Public Offering of Shares 19
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 21
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 23
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 25
Debt Offering 27
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 27
Acquisition 29
Novartis May Acquire Intercept Pharma 29
Intercept Pharmaceuticals Inc – Key Competitors 30
Intercept Pharmaceuticals Inc – Key Employees 31
Intercept Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 34
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 37
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update 39
Nov 03, 2016: Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update 42
Aug 04, 2016: Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update 44
May 05, 2016: Intercept Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update 46
Feb 23, 2016: Intercept Pharmaceuticals Reports 2015 Financial Results and Provides Business Update 47
Corporate Communications 49
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development 49
Jun 09, 2016: Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer 50
Product News 51
Oct 04, 2016: TARGET PharmaSolutions Announces the Launch of TARGET-PBC (Primary Biliary Cholangitis) 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intercept Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Intercept Pharma Raises US$30 Million In Series C Financing 10
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Enters Into Co-Development Agreement With Servier 14
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For INT-747 15
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 17
Intercept Pharma Raises USD202 Million in Public Offering of Shares 19
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 21
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 23
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 25
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 27
Novartis May Acquire Intercept Pharma 29
Intercept Pharmaceuticals Inc, Key Competitors 30
Intercept Pharmaceuticals Inc, Key Employees 31
Intercept Pharmaceuticals Inc, Other Locations 32
Intercept Pharmaceuticals Inc, Subsidiaries 32

★海外企業調査レポート[Intercept Pharmaceuticals Inc (ICPT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Feldan Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Feldan Therapeutics Inc (Feldan), formerly Feldan Bio Inc, is a biotechnology company with focus on the discovery, development, manufacture and marketing of recombinant proteins. The company developed a peptide-based technology platform, the Feldan Shuttle for intracellular delivery of prote …
  • Escher Group Holdings plc:企業の戦略・SWOT・財務情報
    Escher Group Holdings plc - Strategy, SWOT and Corporate Finance Report Summary Escher Group Holdings plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Awilco LNG ASA (ALNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Awilco LNG ASA (Awilco LNG), a subsidiary of Awilhelmsen AS, is an oil and gas company that provides LNG transportation programs. The company owns and operates LNG vessels intended for international trading. It offers LNG value chain such as liquefaction, production, regasification, transpor …
  • HealthSouth Corporation:企業のM&A・事業提携・投資動向
    HealthSouth Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HealthSouth Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • General Mills Inc:戦略・SWOT・企業財務分析
    General Mills Inc - Strategy, SWOT and Corporate Finance Report Summary General Mills Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Central Garden & Pet Company:企業の戦略・SWOT・財務情報
    Central Garden & Pet Company - Strategy, SWOT and Corporate Finance Report Summary Central Garden & Pet Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • NanoString Technologies Inc (NSTG)-医療機器分野:企業M&A・提携分析
    Summary NanoString Technologies Inc (NanoString) is a provider of life science products and tools for translational research and molecular diagnostics. The company's products portfolio includes sprint profiler, Dx analysis system with flex, MAX analysis system, protein assays, solid tumor assays, ge …
  • Mindray Medical International Limited:企業の戦略・SWOT・財務情報
    Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report Summary Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Pernod Ricard SA (RI):企業の財務・戦略的SWOT分析
    Pernod Ricard SA (RI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CarMax, Inc.:戦略・SWOT・企業財務分析
    CarMax, Inc. - Strategy, SWOT and Corporate Finance Report Summary CarMax, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • ESAB Holdings Ltd:企業の戦略・SWOT・財務情報
    ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • VTB Bank:企業の戦略・SWOT・財務情報
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Leoni AG (LEO):企業の財務・戦略的SWOT分析
    Leoni AG (LEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Skinvisible Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Skinvisible Pharmaceuticals Inc (Skinvisible Pharmaceuticals), a subsidiary of Skinvisible Inc, is a pharmaceutical company that develops and manufactures prescription and over the counter dermatology, medical, cosmetic, consumer goods, and skincare products. The company provides products su …
  • Partners HealthCare System Inc:企業の戦略的SWOT分析
    Partners HealthCare System Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Apache Corp (APA):企業の財務・戦略的SWOT分析
    Apache Corp (APA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • BCD Travel Services B.V.:企業の戦略・SWOT・財務情報
    BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report Summary BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Essentra Plc (ESNT):企業の財務・戦略的SWOT分析
    Essentra Plc (ESNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Calixar SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Calixar SAS (Calixar) is a provider of solutions to develop conformational antibodies. The company offers production, Solubilization, extraction, purification, stabilization and crystallization of functional membrane proteins and antigens. It offers technology to discover and validate the po …
  • AnGes Inc (4563):企業の財務・戦略的SWOT分析
    AnGes Inc (4563) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆